Skip to main content

Day: September 5, 2023

eSports Market to Surpass USD 6.75 Billion by 2030, exhibiting a CAGR of 21.5%

The global eSports market size is projected to reach USD 6.75 billion in 2030, at a CAGR of 21.5% during the forecast period, 2023-2030eSports MarketForecast, 2023-2030Pune, India, Sept. 05, 2023 (GLOBE NEWSWIRE) — The global eSports market size was valued at USD 1.45 billion in 2022 and is projected to reach USD 6.75 billion by 2030, exhibiting a CAGR of 21.5% during the forecast period. Fortune Business Insights has presented this information in their latest report titled “Global eSports Market Forecast, 2023-2030.” The concept of live game streaming is gaining immense traction among the younger population as these youngsters can easily access the internet. Many companies are also increasing their investments in a wide range of gaming companies to expand their customer base and appeal to a younger audience....

Continue reading

Data Center Automation Market Size to Surpass USD 27.35 Billion in 2029, exhibiting a CAGR of 18.2%

As per the report by Fortune Business Insights, the global Data Center Automation Market size is projected to reach USD 27.35 billion in 2029, at a CAGR of 18.2% during the forecast period.Data Center Automation MarketForecast, 2022-2029Pune, India, Sept. 05, 2023 (GLOBE NEWSWIRE) — Global Data Center Automation Market size was valued at USD 7.40 billion in 2021 and is projected to reach USD 27.35 billion by 2029, exhibiting a CAGR of 18.2% during the forecast period. Fortune Business Insights™ mentions this information in its report titled Data Center Automation Market Forecast, 2023-2029.Request a Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/data-center-automation-market-107027Key Industry DevelopmentABB entered into a collaboration with ATS Global, a smart digital transformation...

Continue reading

Fingerprint Cards AB (publ) extends the subscription period for warrants of series 2022:1 and 2022:2 and makes certain clarifications

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS), AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE SECTION “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. On 16 July 2023 the board of Fingerprint Cards AB (publ) (“Fingerprints” or the “Company”) announced an extension of the subscription period for warrants of series 2022:1 and 2022:2 (ISIN: SE0018768269 and ISIN: SE0018768277) (together the “Warrants”). The current subscription period ends 14 September 2023. The Company has been...

Continue reading

Sanoma’s Board of Directors has decided the record date and payment date of the second instalment of the dividend for 2022

Sanoma Corporation, Stock Exchange Release, 5 September 2023 at 9:00 EET Sanoma’s Board of Directors has decided the record date and payment date of the second instalment of the dividend for 2022 The Board of Directors of Sanoma Corporation has in its meeting decided the record date and payment date of the second instalment of the dividend for 2022, amounting to EUR 0.13 per share. The second dividend instalment shall be paid to a shareholder who is registered in the shareholders’ register of Sanoma Corporation maintained by Euroclear Finland Ltd on the dividend record date 15 September 2023. The dividend payment date for this instalment is 22 September 2023. The Annual General Meeting of Sanoma Corporation held on 19 April 2023 resolved that for 2022 a dividend of EUR 0.37 shall be paid in three instalments. The first instalment of EUR...

Continue reading

REXEL LAUNCHES A SUSTAINABILITY-LINKED NOTES OFFERING FOR A NOMINAL AMOUNT OF €400 MILLION  

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA REXEL LAUNCHES A SUSTAINABILITY-LINKED NOTES OFFERING FOR A NOMINAL AMOUNT OF €400 MILLION Rexel, a worldwide expert in the multichannel professional distribution of products and services for the energy world, announced today that it intends to offer €400 million of senior unsecured sustainability-linked notes due 2030 (the “Notes”). The Notes, callable at Rexel’s discretion as from September 2026, will rank pari passu with Rexel’s senior credit facility and other senior unsecured notes. Rexel published today its new Sustainability-Linked Financing Framework (the “Framework”) which covers debt instruments whose financial characteristics are linked with sustainability performance targets. The Framework has been established in accordance...

Continue reading

Sanoma’s financial reporting in 2024

Sanoma Corporation, Stock Exchange Release, 5 September 2023 at 9:05 EET Sanoma’s financial reporting in 2024 In 2024, Sanoma Corporation will publish financial information as follows: Full-Year Result 2023                                                          Wednesday, 7 February Interim Report 1 January–31 March 2023                             Wednesday, 8 May Half-Year Report 1 January–30 June 2023                             Wednesday, 24 July Interim Report 1 January–30 September 2023                      Thursday, 31 October Sanoma observes a silent period of 30 days prior to publishing of financial information. Sanoma’s Financial Statements and Directors’ Report for 2023 will be published during week 10, which starts on 4 March 2024. Sanoma Corporation’s Annual General Meeting (AGM) 2024 is planned to be held on Wednesday,...

Continue reading

Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures

Press Release Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures   ISO 13485 certification renewed for manufacturing sites at Gray and Dijon French Health Agency upgrades GMP certification to commercial use U.S. audit readiness of Crossject Dijon and Gray manufacturing sites for a potential FDA audit Dijon, France, September 5, 2023 — Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free autoinjectors for emergency situations, announces that its manufacturing sites in Dijon and Gray (France) have passed an annual ISO certification audit, expanded their scope of certification by French Health Agency, and received positive feedback after an audit by the Biomedical Advanced Research and Development Authority (BARDA),...

Continue reading

Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer

FDA approval of IND for VB-C-04 trial. Nykode to further elaborate on trial design and development strategy at upcoming capital markets day in New York on September 20.OSLO, Norway, Sept. 05, 2023 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced FDA approval of its investigational new drug (IND) application for the Phase 2 clinical trial. The trial is designed to evaluate VB10.16, the Company’s wholly owned off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, in combination with Roche’s PD-L1 inhibitor atezolizumab (Tecentriq®1) in patients with HPV16-positive, PD-L1-positive, recurrent or metastatic cervical cancer. Nykode is on track to initiate the trial in the fourth...

Continue reading

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

Cohort 1 is completed, and Cohort 2 is 80% recruitedAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study is progressing well, with Cohort 1 completed and 80% of patients recruited into Cohort 2. Results evaluating the efficacy, safety and tolerability of ADX71149 in combination with levetiracetam or brivaracetam from patient Cohorts 1 and Cohort 2 are anticipated for the second quarter of 2024. The primary efficacy endpoint of this study is time to baseline monthly seizure count. Collaboration partner Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical...

Continue reading

WISeKey Empowers Luxury Brands with Advanced NFT Technology to Digitally Authenticate and Represent Unique Products

WISeKey Empowers Luxury Brands with Advanced NFT Technology to Digitally Authenticate and Represent Unique Products Secure NFT tags embedded as ePassports can be affixed to any product and create a unique digital footprint. Geneva, Switzerland – September 5, 2023 – WISeKey International Holding Ltd (SIX: WIHN, NASDAQ: WKEY), a leader in cybersecurity, digital identity, and Internet of Things (IoT) solutions operating as a holding company, today announced that it is supporting luxury brands’ efforts to NFT (non-fungible tokens) their products as unique, digital assets, unalterably registered on a blockchain, which can be bought and sold like any other product or commodity. As the world of luxury goods intersects with the digital realm, WISeKey’s trusted NFT technology is ushering in a new era of authentication and representation....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.